Takeda has presented strong phase III data for a psoriasis drug, with its medication outperforming deucravacitinib in a head-to-head study. The company aims for approval of the drug in 2026. Reports indicate the drug, referred to as Zasocitinib, significantly outperformed deucravacitinib, though it is unclear how this development will impact the broader psoriasis treatment landscape.